<DOC>
	<DOCNO>NCT00012012</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining radiation therapy chemotherapy may kill tumor cell . Drugs amifostine may protect normal cell side effect radiation therapy . PURPOSE : Phase I/II trial study effectiveness combine cisplatin radiation therapy without amifostine treat patient stage IIIB stage IVA cancer cervix .</brief_summary>
	<brief_title>Radiation Therapy Cisplatin With Without Amifostine Patients With Stage IIIB IVA Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility tolerability external beam radiotherapy , brachytherapy , cisplatin patient para-aortic high common iliac lymph node-positive carcinoma uterine cervix . - Determine feasibility tolerability regimen addition amifostine patient . - Determine efficacy 2 regimen , term improve pelvic para-aortic tumor control distant metastasis , patient . OUTLINE : - Phase I : Patients undergo external beam radiotherapy pelvis para-aortic region 5 day week 5 week . Patients also undergo either intracavitary low-dose rate ( LDR ) brachytherapy 2 application begin within 2 week completion external beam radiotherapy 2-3 week interval 6 fraction high-dose rate intracavitary brachytherapy 8 week begin early week 2 external beam radiotherapy . Patients also receive cisplatin IV 1 hour weekly 6 week concurrently external beam radiotherapy LDR brachytherapy . Phase II proceeds toxicity phase I within expect parameter . - Phase II : Patients receive external beam radiotherapy , brachytherapy , cisplatin phase I . Patients also receive amifostine subcutaneously daily external beam radiotherapy cisplatin . Treatment continue 8 week absence disease progression unacceptable toxicity . Patients follow every 3 month 2 year , every 4 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , locally advanced carcinoma uterine cervix TNM classification stage IIIB IVA Disease metastatic paraaortic high common iliac lymph node Prior complete surgical resection involve lymph node gross residual tumor involvement lymph node allow The following cellular type eligible : Squamous cell carcinoma Adenocarcinoma Adenosquamous carcinoma The following cellular type ineligible : Small cell carcinoma Carcinoid tumor Glassy cell carcinoma Clear cell carcinoma Cystadenocarcinoma No metastatic disease outside pelvis ( except paraaortic node ) PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy At least 6 month Hematopoietic White blood cell count ( WBC ) least 3,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 mg/dL Alanine amino transferase ( ALT ) great 2 time normal Renal Creatinine great 1.5 mg/dL ( urinary diversion allow ) Corrected calcium normal Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent significant medical condition would preclude study participation No insulindependent diabetes No malignancy within past 3 year except cutaneous basal cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic chemotherapy Endocrine therapy Not specify Radiotherapy No prior pelvic irradiation except transvaginal radiotherapy control bleed Surgery See Disease Characteristics No prior tumordirected surgery except lymph node biopsy/staging</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>radiation toxicity</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>